Literature DB >> 12606131

Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques.

A Martínez-Ramírez1, S Rodríguez-Perales, B Meléndez, B Martínez-Delgado, M Urioste, J C Cigudosa, J Benítez.   

Abstract

The A673 cell line was established from a patient with a primary rhabdomyosarcoma (RMS), which is referred to in the literature either as a Ewing tumor (ET) or as RMS. Although the two tumoral types are associated with specific and well-characterized translocations, no cytogenetic report on this cell line has been published. We characterized the A673 cell line using a combination of spectral karyotyping (SKY), fluorescence in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR), which revealed the presence of a complex karyotype and a translocation involving chromosomes 11 and 22 and the fusion of EWS and FLI1 genes, both events being specific to ET. Neither cytogenetics nor molecular alterations specific to RMS were found.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606131     DOI: 10.1016/s0165-4608(02)00670-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  26 in total

Review 1.  Molecular cytogenetics in translational oncology: when chromosomes meet genomics.

Authors:  M J Calasanz; J C Cigudosa
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

2.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

3.  Molecular cytogenetic characterization of two established ESFT cell lines.

Authors:  Masako Ishiguro; Mutsumi Yuki; Tomoko Fukushige; Mikio Mizoguchi; Yasuhiko Kaneko; Takeshita Morishige; Hiroshi Iwasaki
Journal:  Hum Cell       Date:  2016-09-09       Impact factor: 4.174

4.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Authors:  Aashi Chaturvedi; Laura M Hoffman; Alana L Welm; Stephen L Lessnick; Mary C Beckerle
Journal:  Genes Cancer       Date:  2012-02

5.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

6.  Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity.

Authors:  Wei Guo; Yi Guo; Shun Tang; Huayi Qu; Hui Zhao
Journal:  Clin Orthop Relat Res       Date:  2008-06-19       Impact factor: 4.176

7.  Amyloid precursor-like protein 2 association with HLA class I molecules.

Authors:  Amit Tuli; Mahak Sharma; Xiaojian Wang; Laura C Simone; Haley L Capek; Steven Cate; William H Hildebrand; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2009-01-31       Impact factor: 6.968

8.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

9.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow.

Authors:  Steven G Dubois; C Lorrie Epling; Juli Teague; Katherine K Matthay; Elizabeth Sinclair
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

10.  Imaging dynamic and selective low-complexity domain interactions that control gene transcription.

Authors:  Shasha Chong; Claire Dugast-Darzacq; Zhe Liu; Peng Dong; Gina M Dailey; Claudia Cattoglio; Alec Heckert; Sambashiva Banala; Luke Lavis; Xavier Darzacq; Robert Tjian
Journal:  Science       Date:  2018-06-21       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.